Excretion, Metabolism and Cytochrome P450 Inhibition of Methyl 3,4-Dihydroxybenzoate (MDHB): A Potential Candidate to Treat Neurodegenerative Diseases
- 25 Downloads
Background and Objectives
Methyl 3,4-dihydroxybenzoate (MDHB) has the potential to prevent neurodegenerative diseases (NDDs). The present work investigated its excretion, metabolism, and cytochrome P450-based drug–drug interactions (DDIs).
After intragastric administration of MDHB, the parent drug was assayed in the urine and faeces of mice. Metabolites of MDHB in the urine, faeces, brain, plasma and liver were detected by liquid chromatography–hybrid quadrupole time-of-flight mass spectrometry (LC–QTOF/MS). A cocktail approach was used to evaluate the inhibition of cytochrome P450 isoforms by MDHB.
The cumulative excretion permille of MDHB in the urine and faeces were found to be 0.67 ± 0.31 and 0.49 ± 0.44‰, respectively. A total of 96 metabolites of MDHB were identified, and all IC50 (half-maximal inhibitory concentration) values of MDHB towards cytochrome P450 isoforms were > 100 μM.
The results suggest that MDHB has a low parent drug cumulative excretion percentage and that MDHB has multiple metabolites and is mainly metabolized through the loss of –CH2 and –CO2, the loss of –CH2O, ester bond hydrolysis, the loss of –O and –CO2, isomerization, methylation, sulfate conjugation, the loss of –CH2O and –O and glycine conjugation, glycine conjugation, the loss of two –O groups and alanine conjugation, the loss of –CH2O and –O and glucose conjugation, glucuronidation, glucose conjugation, etc., in vivo. Finally, MDHB has a low probability of cytochrome P450-based DDIs.
Compliance with Ethical Standards
The animal experiments adhered to the Jinan University Medical College Animal Use Ordinance and were approved by the Ethics Committee of the Medical School of Jinan University.
This work was supported by the National Natural Science Foundation of China (grant no. 81473296) and China’s 111 Project (no. B14036).
Conflict of interest
None of the authors have conflicts of interest to declare.
- 1.Ma L, Li JM, Chen YQ, Li Y, Guo XJ. Determination of 3,4-dihydroxy methyl benzoate in Hedyotis diffusa Willd by HPLC. Shizhen Guo Yi Guo Yao. 2009;20(03):528–9.Google Scholar
- 2.Xu WQ, Gong XJ, Zhou X, Zhao C, Chen HG. Chemiacal constituents and bioactivity of Kalimeris indica. China J Chin Materia Med. 2010;35(23):3172–4.Google Scholar
- 9.Hu SH, Wang JH, Mi XN, Pan JP, Wang LF, Zhang J, et al. Neuroprotective effect of methyl 3,4-dihydroxybenzoate on NMDA-induced injury in rat retina. Int J Sci. 2018;5(5):114–29.Google Scholar
- 10.Zhang W, Cai L, Geng HJ, Su CF, Yan L, Wang JH, et al. Methyl 3,4-dihydroxybenzoate extends the lifespan of Caenorhabditis elegans, partly via W06A7.4 gene. Exp Gerontol. 2014;60:108–16.Google Scholar
- 12.Yang BF. Pharmacology, vol. 7. Beijing: People’s Medical Publishing House; 2008.Google Scholar
- 14.Chadrani Gunaratna Bioanalytical Syatems Inc. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part 1. Curr Sep. 2000;19(1):17–23.Google Scholar
- 15.Bandu R, Ahn HS, Lee JW, Kim YW, Choi SH, Kim HJ, et al. Liquid chromatography electrospray ionization tandem mass spectrometric (LC/ESI–MS/MS) study for the identification and characterization of in vivo metabolites of cisplatin in rat kidney cancer tissues: online hydrogen/deuterium (H/D) exchange study. PLoS One. 2015;10(8):e0134027.CrossRefGoogle Scholar
- 17.Peng Y, Wu H, Zhang X, Zhang F, Qi H, Zhong Y, et al. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug–drug interaction evaluation. Xenobiotica. 2015;45(11):961–77.CrossRefGoogle Scholar
- 20.Bi HC. The pharmacokinetic study of tanshinone IIA in rats and the involved mechanisms. Guangzhou: Sun Yat-sen University; 2007.Google Scholar
- 22.Chen JQ, Wang H, Li DY, Qu XT, Zhu FX. Analysis of metabolites of protocatechuic acid in rats in vivo. Chin Trad Patent Med. 2017;39(03):561–4.Google Scholar
- 24.Zhong DF, Zhu MS, Humphreys WG. Drug metabolism in drug design and development-basic concepts and practice, vol. 1. Beijing: People’s Military Medical Press; 2011.Google Scholar
- 26.Jiang YB, Shan JH, Wang Y, Cai YH, Tian YP. Application progress of LC–MS/MS technology in drug metabolism research. Chin J Pharm Anal. 2014;03:385–91.Google Scholar
- 28.Xue XY, Lin LF, Xiao F, Pi T, Lai YC, Luo HM. Neurotrophic effects of protocatechuic acid on neurite outgrowth and survival in cultured cerebral cortical neurons of newborn rat. J Chin Med Mater. 2011;34(4):567–71.Google Scholar
- 33.Schlickmann F, de Souza P, Boeing T, Mariano LNB, Steimbach VMB, Krueger CMA, et al. Chemical composition and diuretic, natriuretic and kaliuretic effects of extracts of Mimosa bimucronata (DC.) Kuntze leaves and its majority constituent methyl gallate in rats. J Pharm Pharmacol. 2017;69(11):1615–24.CrossRefGoogle Scholar
- 35.Bag PK, Roy N, Acharyya S, Saha DR, Koley H, Sarkar P, et al. In vivo fluid accumulation-inhibitory, anticolonization and anti-inflammatory and in vitro biofilm-inhibitory activities of methyl gallate isolated from Terminalia chebula against fluoroquinolones resistant Vibrio cholerae. Microb Pathog. 2019;128:41–6.CrossRefGoogle Scholar
- 43.Zhang PY, Ren J, Zhi WQ, Liu CM, Gao N. Inhibition of CYP450 activity by honokiol and other four components of Chinese traditional medicine in vitro. Chin J Clin Pharmacol Ther. 2017;22(8):922–6.Google Scholar